OncoSec Medical Incorporated · OTC:ONCSQ
OncoSec Medical — Investor Presentation (July 2011)
27 slides from OncoSec Medical's investor presentation, July 2011
Slide 1: OMS ElectroOncology: Precision Tumor Destruction and DNA Based Cancer Immunotherapy
Onc: Sec Medical OMS ElectroOncology Precision Tumor Destruction and DNA Based Cancer Immunotherapy OTCBB: ONCS Punit Dhillon President & CEO Onc::Sec Medical
Slide 2: Forward Looking Statement
Forward Looking Statement Our commentary and responses to your questions may contain forward- looking statements, including comments concerning clinical trials and product development programs, evaluation of potential opportunities, the level of corporate expenditures, the assessment of OncoSec’s te
Slide 3: Investment Overview
Investment Overview • Cancer Therapy with OMS electrochemotherapy and OMS electroimmunotherapy with DNA based cytokines • Ablation platform selectively destroys cancer cells while leaving healthy tissue intact, dramatically improving patient quality of life • Immunotherapy platform allows activation
Slide 4: OncoSec Solution = OMS ElectroOncology
OncoSec Solution = OMS ElectroOncology OncoSec’s treatment platform has two components: Cytokine Chemotherapeutic Plasmid DNA Agent Construct (Bleomycin) (e.g. IL-12) or Drug-device combination • Razor-razor blade marketing strategy with revenue from single use disposable; potential profit from prop
Slide 5: Electroporation Enhances Therapeutic Potency
Electroporation Enhances Therapeutic Potency Anti-cancer agent injected directly into tissue Tissue electroporation enhances cellular uptake Electroporation: millisecond pulses increase cell permeability Drug surrounds Cell poration; Cells reseal, allowing agent cells agent enters cells to perform i
Slide 6: Traditional Cancer Treatments
Traditional Cancer Treatments • Expensive: $50 billion spent on cancer care in the United States each year. • Invasive: Most cancerous tumors are treated surgically and with intravenous chemotherapy. • Debilitating: Recovery time from surgery often takes weeks. • Severe Side Effects: Intravenous che
Slide 7: OMS ElectroOncology Cancer Targets
OMS ElectroOncology Cancer Targets OncoSec’s ElectroOncology has successfully treated a range of solid tumor cancers in humans • Skin (Melanoma and Non-Melanoma) • Head & Neck • Breast • Prostate • Pancreatic 7/12/2011 7
Slide 8: Benefits to the Community
Benefits to the Community OncoSec’s ElectroOncology procedures will be favored by: • Patients: Highly effective and without serious side effects • Doctors: Suitable for a variety of cancers, and allows physicians to treat more patients in less time • Hospitals: Reduces patient operating time and nee
Slide 9: ElectroImmunotherapy
ElectroImmunotherapy • DNA plasmids encoding for cytokines (e.g. IL-12) to stimulate the body’s immune system to kill cancer cells • DNA plasmid encoding for cytokines in combination with OMS increased cellular uptake of DNA immunotherapeutic subsequent production/expression of IL-12 • Induces i
Slide 10: OncoSec's Lead Candidate: IL-12
OncoSec’s Lead Candidate: IL-12 1. DNA IL-12 uptake into tumor cells IL-12 recruits cytotoxic T-cells and macrophages enhanced by electroporation 2. Cells produce and Apoptosis secrete IL-12 TH1 3. IL-12 recruits IFN- macrophages and IL-12 cytotoxic T-cells and Macrophage TH 1 Inhibits activates oth
Slide 11: IL-12 Plasmid in Melanoma Mouse Model - I
IL-12 Plasmid in Melanoma Mouse Model - I Lucas et al., 2002, IL-12 plasmid delivery by in Vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma, Molecular Therapy Intratumoral delivery of IL-12 by electroporation demonstrated: • Cytokine expression within th
Slide 12: IL-12 Plasmid in Melanoma Mouse Model - II
IL-12 Plasmid in Melanoma Mouse Model - II Tumor response at day 30 post-treatment Objective Complete Group Dose Electroporation Response Response Females Males Females Males 1 0.05 mg Saline No 0% 0% 0% 0% 2 0.005 mg IL-12 No 0% 0% 0% 0% 3 0.005 mg IL-12 Yes 20% 20% 20% 20% 4 0.05 mg IL-12 No 20% 0
Slide 13: US Phase I Melanoma Trial Results
US Phase I Melanoma Trial Results • Dose escalation clinical study in patients with metastatic melanoma • Treatment with OMS and IL-12 completed in 24 patients at University of Southern Florida, Moffitt Cancer Center • US Phase I results reported in Journal of Clinical Oncology (Daud et al, 2008): •
Slide 14: Phase II Study Design for OMS-100 (Melanoma)
Phase II Study Design for OMS-100 (Melanoma) Summary of clinical trial design Title: Phase II trial of intratumoral pIL-12 electroporation in advanced stage cutaneous and in transit malignant melanoma Design: Single arm, open-label study Patient population: Melanoma Number of Subjects: 25 Endpoints:
Slide 15: Phase II Study Design for OMS-I110 (MCC)
Phase II Study Design for OMS-I110 (MCC) Summary of Clinical Trial Design: Title: A Phase II Study of Intratumoral Injection of Interleukin-12 Plasmid and in vivo Electroporation in Patients with Merkel Cell Carcinoma Design: Single arm, open-label study Patient Population: Melanoma Number of Subjec
Slide 16: Phase II Study Design for OMS-I120 (CTCL)
Phase II Study Design for OMS-I120 (CTCL) Summary of Clinical Trial Design: Title: Phase II Trial of Intratumoral IL-12 Plasmid Electroporation In Cutaneous Lymphoma Design: Open-label study; Simon’s 2-stage mini-max design Patient Population: Cutaneous T-Cell Lymphoma Number of Subjects: Stage 1 =
Slide 17: OMS ElectroChemotherapy
OMS ElectroChemotherapy • Chemotherapeutic agent (bleomycin) delivered intracellularly with electroporation Chemical based ablation, unlike surgery, radio frequency ablation and cryotherapy that has the ability to selectively kill cancer Clinical and physician experience in late stage head & neck an
Slide 18: Treatment of Head & Neck Cancer
Treatment of Head & Neck Cancer Electrochemotherapy of squamous cell carcinoma Lateral tongue cancer Electrochemotherapy Tumor Electroporation injected applied with with bleomycin applicator 1 day post electrochemotherapy 4 wks post electrochemotherapy No Cancer cells removal destroyed of while heal
Slide 19: Treatment of Skin Cancer
Treatment of Skin Cancer Electrochemotherapy of basal cell cancer BCC of earlobe Tumor cells turn black as they die 30 days Pre- post- treatment treatment Wound healing itself No further evidence of tumor 90 days 120 days post- post- treatment treatment 19
Slide 20: Cutaneous Cancer Therapy Clinical Data
Cutaneous Cancer Therapy Clinical Data (H.Lee Moffitt Cancer Center – University South Florida) Objective Complete Type # of Patients Response* Response Basal Cell 56 of 56 51 of 56 18 Carcinoma (100%) (91.1%) 84 of 85 75 of 85 Melanoma 10 (98.8%) (88.2%) Squamous Cell 1 of 1 0 of 1 1 Carcinoma (100
Slide 21: OncoSec Competitive Advantages
OncoSec Competitive Advantages Compelling stakeholder benefits and promise of market pull • Improved cosmetic, functional and pain outcomes → patient preference • Minimal tissue removal = simple post-op care → physician & payer preference • Transcends tumor types & locations → physician preference •
Slide 22: Board of Directors
Board of Directors • Dr. Avtar Dhillon, MD – Co-founder, Chairman, Independent Director • Executive Chairman, Inovio Pharmaceuticals, Inc. (President & CEO, 2001-2009) • Partnering, M&A, finance, turnaround and restructuring experience (previous turnaround of Cardiome) • Raised over $200 million for
Slide 23: Management Team
Management Team • Punit Dhillon – Co-founder, President & CEO • Dr. Michael Cross, Ph.D. – Co-founder, Chief Operating Officer • 20 years in VC (MDS Capital, Jovian Capital, GrowthWorks) and biotech operations: MDS Inc (Director), MDS Proteomics (VP), Viventia Biotech (COO) - experience financing an
Slide 24: Financial Information
Financial Information Shares Issued & Outstanding: 56,856,000 Warrants: 13,456,000 Stock Option Pool: 5,200,000 Shares Outstanding Fully Diluted: 75,512,000 Management & Affiliates Ownership: 53% Formation Capital: $4.1M 24
Slide 25: Commercialization Milestones
Commercialization Milestones • Based on leveraging large historical patient database • Initiate multiple OMS ElectroImmunotherapy trials for skin cancers • Initiate US pivotal OMS ElectroChemotherapy trials for skin cancer • Extend EU pre-marketing studies demonstrating pharmacoeconomic, reimburseme
Slide 26: Next Steps
Next Steps • Initiate additional clinical trials to further validate safety and efficacy seen in early phase clinical trials using OncoSec’s ElectroImmunotherapy treatment procedure • Initiate Phase IV pre-marketing studies in Europe for OncoSec’s ElectroChemotherapy treatment procedure • Commence F
Slide 27: Business Opportunity Summary
Business Opportunity Summary $1B market for locally effective, tissue sparing tumor treatment Cancer therapy using biologics and small molecules: diversified Market exclusivity through potential orphan indications Market ready with favorable pharmacoeconomics & quality of life benefits Cen